1. The metabolic fate of N,N-dimethylcarbamoylmethyl 4-(4-guanidino[C-
14]benzoyloxy)phenylacetate methanesulphonate (C-14-camostat mesylate)
was investigated after i.v. administration to man (12-h infusion), an
d to rat and dog (bolus injection). 2. Renal excretion (mainly in 24 h
) accounted for al least 80% dose in all three species, and the only t
wo important metabolites were identified as 4-(4-guanidinobenzoyloxy)p
henylacetic acid (GBPA) and 4-guanidinobenzoic acid (GBA). 3. Parent d
rug was not detected in human plasma either during or after infusion o
f C-14-camostat mesylate owing to rapid hydrolysis of the side-chain e
ster group (t(1/2) < 1 min). Steady-stale levels of both GBPA and GBA
in plasma were apparently attained by the end of the infusion period.
Mean terminal half-life, systemic clearance and apparent volume of dis
tribution at steady-state of GBPA in man were 1.0 h, 6.4 ml/min per kg
and 0.38 l/kg, respectively, and the corresponding values for GBA wer
e 2.4 h, 4.7 ml/min per kg and 1.0 l/kg respectively. 4. Radioactivity
was rapidly distributed to most tissues after bolus i.v. doses of C-1
4-camostat mesylate to rats and dogs, with highest levels being associ
ated with the liver and kidney, the two main organs of drug eliminatio
n. Concentrations in the pancreas, a possible site for drug action, we
re generally lower than those in plasma.